Jonathan Mark Hopper - 17 Feb 2023 Form 4 Insider Report for Vericel Corp (VCEL)

Role
Chief Medical Officer
Signature
/s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Issuer symbol
VCEL
Transactions as of
17 Feb 2023
Net transactions value
-$55,465
Form type
4
Filing time
22 Feb 2023, 19:57:40 UTC
Previous filing
14 Feb 2023
Next filing
22 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCEL Common Stock Options Exercise $0 +2,325 +4.6% $0.000000 52,522 18 Feb 2023 Direct F1, F2
transaction VCEL Common Stock Tax liability $33,041 -1,108 -2.1% $29.82 51,414 18 Feb 2023 Direct F2, F3
transaction VCEL Common Stock Options Exercise $0 +1,750 +3.4% $0.000000 53,164 19 Feb 2023 Direct F2, F4
transaction VCEL Common Stock Tax liability $22,425 -752 -1.4% $29.82 52,412 19 Feb 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCEL Stock Option (Right to Buy) Award $0 +1,875 $0.000000 1,875 17 Feb 2023 Common Stock 1,875 $29.82 Direct F5
transaction VCEL Stock Option (Right to Buy) Award $0 +28,125 $0.000000 28,125 17 Feb 2023 Common Stock 28,125 $29.82 Direct F5
transaction VCEL Restricted Stock Unit Award $0 +12,000 $0.000000 12,000 17 Feb 2023 Common Stock 12,000 Direct F6, F7, F8
transaction VCEL Restricted Stock Unit Options Exercise -2,325 -25% 6,975 18 Feb 2023 Common Stock 2,325 Direct F1, F6, F8, F9
transaction VCEL Restricted Stock Unit Options Exercise -1,750 -33% 3,500 19 Feb 2023 Common Stock 1,750 Direct F4, F6, F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026.
F2 These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F3 These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units.
F4 The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2024 and February 19, 2025.
F5 These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.
F6 Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F7 These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 17, 2024. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively.
F8 No expiration date for this type of award.
F9 The Fair Market Value of the vested derivative securities is $29.82 per share.